hero image

Biogen Issues First Progress Report of its Signature Healthy Climate, Healthy Lives™ Initiative

September 23, 2021 Company Statements

September 23, 2021 – In 2020, Biogen launched its signature Healthy Climate, Healthy Lives™ initiative, a groundbreaking $250 million, 20-year commitment to address the deeply interrelated issues of climate, health, and equity. Biogen is the first Fortune 500 company to commit to becoming fossil fuel free and established new emissions reduction targets in line with the Science Based Targets initiative, consistent with levels required to meet the goals of the Paris Agreement.

Today’s progress report details the company’s efforts to go fossil fuel free, including engagement with its employees and suppliers, and ongoing collaborations with renowned institutions to improve health – especially for vulnerable populations most impacted by climate-related events.

Biogen continues to take its role as a leader on climate and health seriously and will continue to advance this work with a sense of urgency in order to promote a world that is healthy, equitable, and sustainable for all.

To learn more and read our one-year progress report, please visit biogen.com/hchl 

thumb
October 20, 2021
Biogen Reports Third Quarter 2021 Results
thumb
October 19, 2021
Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022

Following the pre-NDA meeting, the companies confirmed t he current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD The planned initial submission package will be for the treatment of MDD with an anticipated PPD filing thereafter